• 2-NBDG Workflows for Cellular Glucose Uptake

  2026-09-09

  Build a quantitative 2-NBDG assay for flow cytometry, microscopy, or plate reading, then adapt it to mechanistic studies of glycolysis and the Warburg effect. The workflow combines practical starting conditions with model-specific kinetic controls, solubility guidance, and interpretation limits for cancer, toxicology, neuronal, and diabetes research.

• Beyond BRD4: A Translational Strategy for (+)-JQ1

  2026-09-08

  A thought-leadership guide to using Bromodomain Inhibitor, (+)-JQ1 as a mechanistic research tool across BRD4 biology, ferroptosis, apoptosis, inflammation, and BRDT-linked reproductive studies—while keeping evidence, assay design, and translational maturity clearly separated.

• 2'3'-cGAMP Workflow for STING Assays

  2026-09-08

  Build a reproducible STING activation workflow with 2'3'-cGAMP (sodium salt), from aqueous stock preparation through TBK1, IRF3, and IFN-β readouts. The guide also shows how a cGAMP challenge can distinguish defective DNA sensing from altered STING stability in antiviral and immunotherapy research.

• Cyanine 3 Tyramide for Neural Signal Amplification

  2026-09-07

  Cyanine 3 Tyramide converts weak molecular signals into bright, spatially localized fluorescence for brain-section imaging, immunohistochemistry, in situ hybridization, and selected flow workflows. This guide translates findings on oxytocin signaling and early life adversity into practical assay design, optimization, and troubleshooting decisions.

• Bromodomain Inhibitor (+)-JQ1: Assay Workflows

  2026-09-07

  Build more informative BET response experiments with (+)-JQ1 by separating growth arrest from true cell killing. This workflow connects BRD4 biology to apoptosis assay design while supporting carefully bounded studies of BRDT inhibition and cytokine modulation.

• Quizartinib (AC220): A Resistance-Aware FLT3 Assay Framework

  2026-09-05

  Quizartinib (AC220) enables a resistance-aware approach to FLT3 biology, connecting target engagement, downstream signaling, leukemia-cell dependence, and xenograft response. This article translates product pharmacology and FLT3-TAZ research into practical assay decisions for acute myeloid leukemia (AML) research.

• Resazurin Assays in Sclerosteosis Translation

  2026-09-04

  A translational framework for using redox-based viability data to distinguish cytotoxicity from osteoblast pathway modulation during PORCN inhibition research in sclerosteosis.

• ECL Chemiluminescent Substrate Detection Kit for PRDX5

  2026-09-04

  See how hypersensitive HRP-based detection can strengthen PRDX5 immunoblotting in retinal ischemia-reperfusion models, especially when sample or antibody is limited. The workflow combines low-picogram sensitivity, extended signal availability, membrane-specific optimization, and practical troubleshooting for more reliable western blot results.

• NETs in CML: TKI-Dependent Vascular Risk Signals

  2026-09-03

  The reference study shows that neutrophil extracellular traps are elevated in treatment-naive chronic myeloid leukemia and can be differentially modulated by tyrosine kinase inhibitors. Its combination of patient-derived neutrophils with a BCR-ABL1-transduced differentiation model links leukemia-associated neutrophil priming to a testable mechanism for vascular toxicity.

• 5X Protein Loading Buffer (Reducing) Guide

  2026-09-03

  5X Protein Loading Buffer (Reducing) simplifies denaturing, reducing protein sample preparation for conventional SDS-PAGE electrophoresis by combining SDS, a sulfhydryl reducing agent, buffer salts, and tracking dye. It is intended for molecular weight-based protein separation and should not be used for native, non-reducing, or disulfide-dependent analyses.

• Sulfo-NHS-SS-Biotin: Reliable Cell-Surface Workflows

  2026-09-02

  Learn how Sulfo-NHS-SS-Biotin (SKU A8005) supports reproducible cell-surface protein labeling, affinity purification, and mechanistic interpretation alongside viability or cytotoxicity assays. This scenario-based guide covers compatibility, fresh preparation, cleavable labeling, data controls, and practical product-selection criteria.

• Matrine Assay Workflows for Cancer and Inflammation

  2026-09-02

  Matrine supports a practical, multi-endpoint workflow spanning tumor-cell viability, stemness, apoptosis, and inflammatory signaling. This guide translates recent thymoma findings into concentration-aware assays while highlighting formulation, controls, and interpretation limits.

• Biomimetic α-Cyperone Nanoparticles in KGN Inflammation

  2026-09-01

  The reference study develops PLGA@AC@FSHL-M biomimetic nanoparticles to deliver α-cyperone to LPS-challenged KGN granulosa cells. Its findings connect reduced inflammatory cytokines and oxidative stress with Nrf2/HO-1 activation, while also highlighting the need for in vivo validation before relevance to diminished ovarian reserve can be established.

• Plerixafor (AMD3100) Research Workflows

  2026-09-01

  Plerixafor (AMD3100) provides a practical way to perturb CXCL12/CXCR4 signaling in cancer, stem-cell, and immune-cell trafficking assays. This workflow-focused guide explains how to prepare the compound, select readouts, translate platelet-extravasation findings into assay design, and troubleshoot common failures.

• Balsalazide in Active Ulcerative Colitis: 2009 Review

  2026-08-31

  The 2009 review by Wiggins and Rajapakse evaluated balsalazide as a colon-targeted 5-aminosalicylate prodrug for mild-to-moderate active ulcerative colitis. Its central finding was that bacterial azoreduction enables colonic release of 5-aminosalicylic acid, with clinical evidence suggesting faster and more frequent remission than mesalamine and a broadly comparable safety profile.

7928 records 1/529 page Next 12345 下5页 Last page